Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St
… and key opinion leaders and introduced next-generation Axiomer ® RNA technology platform. LEIDEN, the Netherlands, … trial in 2018. Beyond that, we are excited about the Axiomer ® platform technology we announced at our R&D day. … the event, the Company also introduced its next-generation Axiomer ® RNA technology platform, which has the potential to …
… to ProQR’s novel RNA editing platform technology called Axiomer LEIDEN, the Netherlands, May 09, 2017 (GLOBE … led to a novel proprietary RNA editing platform, called Axiomer, which in our view is the next step in RNA …
… transformative RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform, today announced … is pioneering a next-generation RNA technology called Axiomer™, which uses a cell’s own editing machinery called …
… supports ProQR’s strategic focus on its proprietary Axiomer ® RNA editing technology platform and continued … of ProQR. “We look forward to continuing to advance our Axiomer RNA editing platform, with an initial focus on … is pioneering a next-generation RNA technology called Axiomer ® , which uses a cell’s own editing machinery called …